Clinical Trial Update: Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease [Phase 2]

View source ↗

Summary

A Phase II trial of thalidomide in refractory/relapsed diffuse large B-cell lymphoma and Hodgkin lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Thalomid (thalidomide)

Snippet

Sponsor: Emory University | Conditions: B-Cell Lymphoma, Hodgkin's Disease | Phase 2 | Status: TERMINATED